Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
This 48 week study is designed to compare the substitution of the thymidine analogues
zidovudine (ZDV) or stavudine (D4T) with either tenofovir DF or abacavir, in patients treated
with highly active antiretroviral therapy (HAART), and show improved outcomes on total limb
fat mass, improved body shape by dual energy x-ray absorptiometry (DEXA) and computed
tomography (CT) scans and improved cholesterol and tryglicerides.